A practical reference on heptapeptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-12-26. Anything still debated is marked as such rather than presented as settled.
Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.
Enzymatic stability motivates the extra three residues at the carboxyl end. Native tuftsin is cleaved quickly by circulating aminopeptidases and carboxypeptidases, which limits its duration of action and its usefulness as a tool compound. Extending the chain with proline-rich segments is a common design tactic because proline constrains the backbone and slows proteolysis. The same Pro-Gly-Pro motif appears in other Russian-developed peptides of the era. Whether the full seven-residue chain is required for activity, or whether it acts mainly as a prodrug releasing tuftsin, remains unresolved.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Tuftsin analogue with a C-terminal Pro-Gly-Pro tail |
| Amino acid sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Abbreviated TKPRPGP in most catalogues |
| Molecular mass | About 752 Da | Value for the free peptide |
| Solubility | Freely soluble in water | Aqueous solutions are kept cold and used promptly |
| Typical storage | -20 °C, dry, protected from light | Applies to the lyophilised powder before reconstitution |
Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.
Reported pharmacological effects center on reduced anxiety-like behavior in animal models and on measures of memory and learning. Proposed contributing mechanisms include modulation of GABAergic signaling, shifts in monoamine turnover, and changes in the activity of enzymes that degrade neuropeptides. Effects on the expression of genes linked to neuroplasticity have also been described. No single molecular target is widely accepted, and whether the behavioral findings arise from one pathway or several remains an open question.
Lyophilized selank is normally supplied as a dry powder and is considered stable for extended periods when kept cold and dry. Moisture uptake is the main practical threat, because absorbed water promotes both hydrolysis and aggregation in the solid state. Vials are usually warmed to room temperature before opening so that condensation does not form on the powder. Supplier documentation commonly specifies -20 °C for routine storage, with -80 °C used for material intended to be archived for years.
Once dissolved, the peptide is markedly less stable than the dry powder. Aqueous solutions are subject to backbone hydrolysis and to microbial growth when they are handled without sterile technique. Buffered solutions near neutral pH are common for short-term laboratory work, while acidic conditions are sometimes used to improve solubility. Analytical laboratories generally prepare working solutions fresh rather than storing them, and a residual water film left in a reopened vial can seed degradation even when the container appears dry.
=== MB-003 === MB-003 is a cocktail of three humanized or human–mouse chimeric mAbs: c13C6, h13F6, and c6D8. A study published in September 2012 found that rhesus macaques infected with Ebola virus (EBOV) survived when receiving MB-003 (mixture of 3 chimeric monoclonal antibodies) one hour after infection. When treated 24 or 48 hours after infection, four of six animals survived and had little to no viremia and few, if any, clinical symptoms. MB-003 was created by scientists at the U.S. Army Medical Research Institute of Infectious Diseases, Gene Olinger, and Jamie Pettitt in collaboration with Mapp Biopharmaceutical with years of funding from US government agencies including the National Institute of Allergy and Infectious Disease, Biomedical Advanced Research and Development Authority, and the Defense Threat Reduction Agency.
A sperm bank, semen bank, or cryobank is a facility that purchases, stores, and sells human semen. The semen is produced and sold by men who are known as sperm donors. The sperm is purchased by other persons for the purpose of achieving a pregnancy other than by a sexual partner. Sperm sold by a sperm donor is known as donor sperm. A sperm bank may be a separate entity supplying donor sperm to individuals or to fertility clinics, or it may be a facility which is run by a clinic for their customers. A pregnancy may be achieved using donor sperm for insemination with similar outcomes to sexual intercourse. By using sperm from a donor rather than from the sperm recipient's partner, the process is a form of third party reproduction. In the 21st century artificial insemination with donor sperm from a sperm bank is most commonly used for individuals with no male partner, such as single women and coupled lesbians. A sperm donor must generally meet specific requirements regarding age and screening for adverse medical history. In the United States, sperm banks are regulated as Human Cell and Tissue or Cell and Tissue Bank Product (HCT/Ps) establishments by the Food and Drug Administration. Many states in the U.S. also have regulations in addition to those imposed by the FDA. In the European Union a sperm bank must have a license, according to the EU Tissue Directive. In the United Kingdom, sperm banks are regulated by the Human Fertilisation and Embryology Authority.
===== MeSH D08.811.682.657 – oxidoreductases acting on aldehyde or oxo group donors ===== MeSH D08.811.682.657.163 – aldehyde oxidoreductases MeSH D08.811.682.657.163.249 – aldehyde dehydrogenase MeSH D08.811.682.657.163.249.750 – omega-crystallins MeSH D08.811.682.657.163.311 – aldehyde oxidase MeSH D08.811.682.657.163.342 – aminomuconate-semialdehyde dehydrogenase MeSH D08.811.682.657.163.374 – aspartate-semialdehyde dehydrogenase MeSH D08.811.682.657.163.468 – benzaldehyde dehydrogenase (NADP+) MeSH D08.811.682.657.163.515 – betaine-aldehyde dehydrogenase MeSH D08.811.682.657.163.562 – glutamate-5-semialdehyde dehydrogenase MeSH D08.811.682.657.163.750 – glyceraldehyde-3-phosphate dehydrogenases MeSH D08.811.682.657.163.750.250 – glyceraldehyde 3-phosphate dehydrogenase (nadp+) MeSH D08.811.682.657.163.750.300 – glyceraldehyde-3-phosphate dehydrogenase (nadp+)(phosphorylating) MeSH D08.811.682.657.163.750.350 – glyceraldehyde-3-phosphate dehydrogenase (phosphorylating) MeSH D08.811.682.657.163.781 – glycolaldehyde dehydrogenase MeSH D08.811.682.657.163.796 – l-aminoadipate-semialdehyde dehydrogenase MeSH D08.811.682.657.163.812 – malonate-semialdehyde dehydrogenase (acetylating) MeSH D08.811.682.657.163.827 – methylmalonate-semialdehyde dehydrogenase (acylating) MeSH D08.811.682.657.163.835 – retinal dehydrogenase MeSH D08.811.682.657.163.843 – succinate-semialdehyde dehydrogenase MeSH D08.811.682.657.163.875 – succinate-semialdehyde dehydrogenase (NAD(P)+) MeSH D08.811.682.657.180 – formate dehydrogenases MeSH D08.811.682.657.350 – ketone oxidoreductases MeSH D08.811.682.657.350.750 – ketoglutarate dehydrogenase complex MeSH D08.811.682.657.350.750.500 – dihydrolipoamide dehydrogenase MeSH D08.811.682.657.350.760 – 3-methyl-2-oxobutanoate dehydrogenase (lipoamide) MeSH D08.811.682.657.350.825 – 2-oxoisovalerate dehydrogenase (acylating) MeSH D08.811.682.657.350.875 – pyruvate dehydrogenase (lipoamide) MeSH D08.811.682.657.350.937 – pyruvate oxidase MeSH D08.811.682.657.350.968 – pyruvate synthase
NOESY-Based Strategy for Assignments of Backbone and Side Chain Resonances of Large Proteins without Deuteration (a protocol) relax Software for the analysis of NMR dynamics ProSA-web Archived 2011-05-11 at the Wayback Machine Web service for the recognition of errors in experimentally or theoretically determined protein structures Protein structure determination from sparse experimental data - an introductory presentation Protein NMR Protein NMR experiments
Before Roemer's time in office, Louisiana had no limits on individual campaign contributions, which allowed donors to cut massive checks to campaigns without reporting the contributions. Roemer placed Kennedy in charge of his quest to toughen campaign finance laws, including placing a $5,000 cap on individual contributions to statewide candidates. In addition to ushering in the passage of campaign finance and product liability reforms for Roemer's administration, Kennedy led the effort to consolidate Louisiana's four boards of higher education into one. He said the policy would be "fundamental" to improving Louisiana universities' "quality and desegregation". That effort eventually came one vote short of passage. Roemer lost his reelection bid in 1991, but ran again in 1995 with Kennedy as his campaign manager. Roemer later endorsed Kennedy's bids for Senate. Kennedy remained close to Roemer until his death in 2021 and credited the former governor for getting him involved in public service.
Sources: en.wikipedia.org
=== Disorders of lipoid metabolism === 272 Disorders of lipoid metabolism 272.0 Pure hypercholesterolemia Fredrickson Type IIa hyperlipoproteinemia Familial hypercholesterolemia 272.1 Pure hyperglyceridemia Hypertriglyceridemia, essential Fredrickson Type IV hyperlipoproteinemia 272.2 Hyperlipidemia, mixed Fredrickson Type IIb or III hyperlipoproteinemia Tubo-eruptive xanthoma Xanthoma tuberosum 272.3 Hyperchylomicronemia Bürger-Grütz syndrome Fredrickson type I or V hyperlipoproteinemia Hyperlipidemia, Group D Mixed hyperglyceridemia 272.4 Other and unspecified hyperlipidemia Alpha-lipoproteinemia Combined hyperlipidemia 272.5 Lipoprotein deficiencies Abetalipoproteinemia Bassen-Kornzweig syndrome High-density lipoid deficiency Hypoalphalipoproteinemia Hypobetalipoproteinemia (familial) 272.6 Lipodystrophy 272.7 Lipidoses Gaucher's disease Niemann-Pick disease Sea-blue histiocyte syndrome 272.8 Other disorders of lipoid metabolism
Small, medium, and large veins The small veins merge to feed as tributaries into medium-sized veins. The medium veins feed into the large veins which include the internal jugular, and renal veins, and the venae cavae that carry the blood directly into the heart. The venae cavae enter the right atrium of the heart from above and below. From above, the superior vena cava carries blood from the arms, head, and chest to the right atrium of the heart, and from below, the inferior vena cava carries blood from the legs and abdomen to the right atrium. The inferior vena cava is the larger of the two. The inferior vena cava is retroperitoneal and runs to the right and roughly parallel to the abdominal aorta along the spine.
In the modern bodybuilding industry, the term "professional" generally means a bodybuilder who has won qualifying competitions as an amateur and has earned a "pro card" from their respective organization. Professionals earn the right to compete in competitions that include monetary prizes. A pro card also prohibits the athlete from competing in federations other than the one from which they have received the pro card. Depending on the level of success, these bodybuilders may receive monetary compensation from sponsors, much like athletes in other sports.
=== The 1990s === The success of Cycles led to the release of 1991's Brotherhood, also on Capitol. The group members grew their hair back out, wore denim and leather, and attempted to revive their biker image of the early 1970s. In spite of the makeover and strong material led by Simmons' now trademark "Dangerous" (featured in the Brian Bosworth biker film Stone Cold), Brotherhood was unsuccessful, in part due to a lack of support from Capitol Records, who dropped the group from their roster by the end of 1991. The accompanying tour (the 1989 lineup minus Bumpus), which also featured Joe Walsh on the bill, ranked among the ten least profitable tours of the 1991 summer season by the North American Concert Promoters Association, and after losing the Capitol deal, the group was inactive by the end of '91, its future uncertain. The 1987 Doobie Brothers alumni band reunited on October 17 and 19, 1992, at the Concord Pavilion in Concord, California to perform benefit shows for LaKind's children. LaKind, terminally ill with colon cancer, joined the group on percussion for a few numbers. The concerts were recorded and subsequently broadcast on the Superstars in Concert radio series accompanied by a plea for contributions to the LaKind family fund. LaKind died on December 24, 1992, at the age of 47. Another brief hiatus followed during which Simmons collaborated with bassist and songwriter John Cowan (ex-New Grass Revival), Rusty Young (of Poco) and Bill Lloyd (of Foster & Lloyd) on an unreleased project called Four Wheel Drive.
Sources: en.wikipedia.org
Selank is a seven-amino-acid peptide built from the tuftsin sequence plus a Pro-Gly-Pro tail. It is produced by chemical synthesis rather than extracted from a natural source. The free peptide is usually supplied as a lyophilised powder or in an aqueous formulation.
Tuftsin is a natural tetrapeptide derived from the Fc portion of immunoglobulin G. Selank retains that tetrapeptide at its N-terminus and adds three residues to improve resistance to enzymatic breakdown. The relationship is structural, and the two molecules are not interchangeable in experimental work.
It holds a product registration in Russia for intranasal use as an anxiolytic. Registrations of that kind are not automatically accepted by regulators elsewhere. In most other countries it is treated as an unapproved substance or a research material.
Reports describe modulation of GABA signalling, changes in monoamine turnover and effects on neurotrophic factor expression. These observations come mainly from animal and cell studies. A single unifying mechanism has not been demonstrated.